Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907

Cornell University, Итак, New York, United States
Journal of Clinical Oncology (Impact Factor: 17.88). 02/2011; 29(8):1022-8. DOI: 10.1200/JCO.2010.29.9859
Source: PubMed

ABSTRACT A phase III trial (Cancer and Leukemia Group B CALGB-49907) was conducted to test whether older patients with early-stage breast cancer would have equivalent relapse-free and overall survival with capecitabine compared with standard chemotherapy. The quality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better QoL than standard chemotherapy.
QoL was assessed in 350 patients randomly assigned to either standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin and cyclophosphamide [AC]; n = 182) or capecitabine (n = 168). Patients were interviewed by telephone before treatment (baseline), midtreatment, within 1 month post-treatment, and at 12, 18, and 24 months postbaseline by using questionnaires from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), a breast systemic adverse effects scale (EORTC BR23), and the Hospital Anxiety and Depression Scale (HADS).
Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P ≤ .005). Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P ≤ .004), but worse hand-foot syndrome and diarrhea (P < .005). These differences all resolved by 12 months.
Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer. Although capecitabine was associated with better QoL during treatment, QoL was similar for both groups at 1 year. The brief period of poorer QoL with standard treatment is a modest price to pay for a chance at improved survival.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The issue of systemic treatment for early breast cancer in the elderly has always been challenging and in spite of the clear evidence of the potential benefits of adjuvant treatment in older women, they are usually undertreated with the potential consequence of worse outcomes.Areas covered: This article will review the evidence surrounding the various systemic options in the treatment armamentarium of early-stage breast cancer in elderly patients. The risks and benefits, with particular attention to a number of newly introduced targeted agents, along with the potential role of incorporating a combined geriatric/oncologic assessment as a routine part of the management of elderly patients with breast cancer are considered.Expert opinion: Administration of available options for (neo)adjuvant endocrine, chemo, as well as targeted therapeutics in fit elderly patients is feasible and tolerable; however, a routine input from geriatric medicine and psycho-oncology experts as well as the training of specialized oncology staff with special interest in geriatric oncology are believed to improve the outcome of elderly patients.
    Expert Opinion on Drug Safety 09/2014; 13(11). DOI:10.1517/14740338.2014.955848 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Patients ≥ 65 years old (“older”) are often not included in randomized clinical trials (RCT), but when they are, care in an RCT might improve quality of life (QoL). We conducted a prospective comparison of QoL among older women receiving standard chemotherapy from the same cooperative group physicians in an RCT vs. an observational study (“off-trial”). Methods Older women with invasive, non-metastatic breast cancer (n = 150 RCT; 530 off-trial) were included. Linear mixed-effects models tested associations between chemotherapy on- vs. off-trial and changes in EORTC (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire) QoL scores over 24 months, controlling for pre-treatment QoL, age, education, tumor factors, comorbidity, and other covariates. Results Anthracycline regimens were used by 58% of women treated on-trial vs. 54% of those treated off-trial. Women in the RCT reported an adjusted mean increase of 13.7 points (95% CI 10.2, 17.1) in global QoL at 24 months (vs. mid-treatment), while women treated off-trial had only an adjusted improvement of 7.0 points (95% CI 3.5, 10.4; p = .007 for difference in mean changes). Women in the RCT had significantly greater improvement in emotional function than those treated off-trial, controlling for baseline; they also had greater reductions in therapy side effects and fatigue at 24 months than women off-trial, controlling for covariates. Conclusion There may be different QoL trajectories for older women undergoing breast cancer chemotherapy on- vs. off-trial. If confirmed, the results suggest that the extra monitoring and communication within an RCT could provide the infrastructure for interventions to address symptoms and improve QoL for the growing older cancer population.
    Journal of Geriatric Oncology 10/2013; 4(4):353–361. DOI:10.1016/j.jgo.2013.05.004 · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction. Breast cancer affects over 200,000 women each year; however, with earlier diagnosis and more effective treatment, patients are living longer, even in the presence of metastatic disease. Current estimates place patients with breast cancer as the largest population of cancer survivors in the United States. Given the successes in treatment, quality of life (QOL) of breast cancer survivors has become a more important consideration. Aim. The aim of this study is to examine QOL throughout the cancer journey. Methods. The cancer journey will be conceptualized across disease states. Main Outcome Measures. Understanding of the longitudinal journey associated with dynamic changes in physical, mental, and psychosocial spheres that occur with cancer, cancer treatment, and the sequelae of both. Conceptualization of changes is shown through the QOL as the survivor moves through the phases of cancer. Results. QOL is not a static concept, and breast cancer survivors undergo dynamic changes in QOL starting at diagnosis, as they progress through treatment and enter posttreatment. Some domains that make up QOL (i.e., sexual functioning and role functioning) can show persistent detriments related to cancer and its treatment. Conclusions. In this article, we will provide a snapshot of some research performed to better understand the QOL of breast cancer survivors using a disease states model of breast cancer. Gao J and Dizon DS. Preparing for survivorship: quality of life in breast cancer survivors. J Sex Med 2013;10(suppl 1):16–20.
    Journal of Sexual Medicine 02/2013; 10(S1). DOI:10.1111/jsm.12029 · 3.15 Impact Factor

Full-text (2 Sources)

Available from
Oct 23, 2014